Author: Ines Martins / Source: Breast Cancer News Adding the CDK4/6 inhibitor abemaciclib to Faslodex (fulvestrant) is a promising way to treat patients with an advanced breast cancer who...
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer,...
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved progression-free survival in postmenopausal women with hormone receptor–positive advanced breast cancer,...